#India #Mumbai #GHG emissions #Piramal Pharma Limited #Biomass Briquettes

Piramal Pharma Takes Bold Steps Towards Sustainability

Piramal Pharma Limited, one of India’s leading pharmaceutical companies, has made significant strides in its sustainability efforts by converting its coal-fired steam boiler at its Digwal production facility to operate using biomass briquettes. This transformational shift is not just a technical upgrade; it represents a profound commitment to environmental stewardship.

A Step Towards Decarbonization

The conversion project, underway as part of Piramal’s broader strategy to combat climate change, aims to cut down approximately 24,000 tonnes of carbon dioxide equivalent (tCO2e) greenhouse gas (GHG) emissions every year. This drastic reduction is projected to account for about 17% of the company’s overall GHG emissions and aligns with its goal of lowering Scope 1 and 2 emissions by 42% by 2030. Nandini Piramal, Chairperson of Piramal Pharma Ltd, emphasizes that this contribution aligns with global climate action frameworks, expressing the company’s dedication to a sustainable future.

What Are Biomass Briquettes?

Biomass briquettes, the renewable energy source being utilized, are created from compressed agricultural waste materials. The transformative power of these briquettes lies in their ability to repurpose organic by-products, thereby supporting a circular economy that minimizes waste while maximizing sustainability. This process reduces reliance on fossil fuels, further reinforcing the pharmaceutical company’s commitment to environmentally responsible manufacturing.

Industry Leadership in Sustainability

Peter DeYoung, CEO of Piramal Global Pharma, highlighted that the shift to biomass briquettes at the Digwal facility is a pioneering move, setting a potential new standard for sustainable practices in the pharmaceutical manufacturing sector. This is not just a single facility upgrade but rather a glimpse into the future of pharmaceutical operations, where innovative strategies and sustainable practices meld seamlessly.

Piramal’s dedication to reducing its environmental footprint exhibits how businesses in the pharmaceutical industry can embrace sustainable methodologies without compromising operational excellence. The transition to bio-friendly practices serves as a framework for other industry players aiming to incorporate effective climate solution strategies.

View of the Future

As Piramal Pharma Limited continues to fortify its commitment to responsible growth through environmentally friendly practices, this initiative symbolizes a broader movement within the industry toward sustainability that will benefit future generations. By adopting innovative technologies and renewable energy sources, Piramal sets a benchmark for others in the industry, proving that reducing GHG emissions and maintaining productivity can go hand in hand.

About Piramal Pharma

Piramal Pharma Limited is known for its diverse portfolio and operational reach across global markets. It operates 17 facilities worldwide and distributes its products in over 100 countries. The offerings include contract development and manufacturing services through Piramal Pharma Solutions, complex hospital generics through Piramal Critical Care, and over-the-counter consumer products in the Indian Consumer Healthcare sector. Moreover, with a joint venture, Abbvie Therapeutics India Private Limited, they are recognized as leaders in the ophthalmology segment within the Indian pharmaceutical market. Piramal’s comprehensive operations and commitment to innovation exemplify its role as a leader not only in pharmaceuticals but also in sustainability practices in the industry.